Kairos Pharma Ltd (KAPA)

$0.65 +0.01 (1.41%)
Market Cap 10.78M
Revenue (ttm) 0.00
Net Income (ttm) -2.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 484,800
Avg Vol 941,450
Day's Range N/A - N/A
Shares Out 16.85M
Stochastic %K 80%
Beta N/A
Analysts Strong Sell
Price Target $8.33

Company Profile

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune respons...

Industry: Biotechnology
Sector: Healthcare
Phone: 310-948-2356
Address:
2355 Westwood Boulevard, Suite 139, Los Angeles, United States
SpartanVI
SpartanVI Jun. 25 at 7:54 AM
$KAPA looks ready for a move soon
0 · Reply
NL1211
NL1211 Jun. 24 at 8:40 PM
$KAPA guys, i am following this Kapa since many months. CEO said this month initial data. is it delayed or still in next 4 working days ?
0 · Reply
StrawberryRips
StrawberryRips Jun. 24 at 7:59 PM
$KAPA going green w a bullish hammer on the daily candle 👀
0 · Reply
StrawberryRips
StrawberryRips Jun. 24 at 6:58 PM
$KAPA weekly MACD curling… read it out
1 · Reply
SteadyTrade55
SteadyTrade55 Jun. 24 at 5:32 PM
$KAPA bull flag, on the 1 week chart. Basing beautifully
1 · Reply
lovestockstwits
lovestockstwits Jun. 24 at 4:45 PM
$KAPA worthless stock ..only stock red today
1 · Reply
Xtracked
Xtracked Jun. 24 at 2:04 PM
$KAPA Final dip! Last chance to load up. Healthy movement
0 · Reply
Winning_calls
Winning_calls Jun. 24 at 12:19 PM
$KAPA 😘😘🤞
0 · Reply
KingJames_
KingJames_ Jun. 24 at 12:08 AM
$KAPA ENV105 is meeting an unmet medical need with drug resistance. Big pharma is going to jump all over this!! This is going $9+
0 · Reply
StrawberryRips
StrawberryRips Jun. 23 at 8:35 PM
$KAPA FDA PHASE 2 Effectiveness Readout any minute now. Drug: ENV105 to combat cancer drug resistance. -aims to reverse the resistance that cancer cells develop against treatments. -only 1/100,000 patients beat cancer without treatment. Treatments are very necessary, so resistance to treatments can greatly affect the outcome of beating cancer. If the Phase 2 results are good this company is sitting on a breakthrough cancer treatment assistance drug. Small float, recently listed in 2024 so this isn’t your regular penny-stock reverse split rinse and repeat type of stock. High price targets on this one too: $4-12. Easy buy and hold.
2 · Reply
Latest News on KAPA
Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Jun 3, 2025, 8:15 AM EDT - 21 days ago

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Kairos Pharma, Ltd. Announces Participation in the D.

May 6, 2025, 8:00 AM EDT - 7 weeks ago

Kairos Pharma, Ltd. Announces Participation in the D.

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 2 months ago

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Kairos Pharma Ltd. Provides Letter to Stockholders

Apr 24, 2025, 8:00 AM EDT - 2 months ago

Kairos Pharma Ltd. Provides Letter to Stockholders

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Apr 17, 2025, 8:00 AM EDT - 2 months ago

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Mar 31, 2025, 7:00 AM EDT - 3 months ago

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Mar 27, 2025, 4:05 PM EDT - 3 months ago

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Mar 20, 2025, 7:30 AM EDT - 3 months ago

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

Feb 26, 2025, 7:00 AM EST - 4 months ago

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Feb 18, 2025, 8:30 AM EST - 4 months ago

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Feb 11, 2025, 8:30 AM EST - 4 months ago

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Feb 6, 2025, 8:30 AM EST - 4 months ago

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Jan 28, 2025, 8:15 AM EST - 5 months ago

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Kairos Pharma Provides Business Update and Outlook into 2025

Jan 21, 2025, 8:30 AM EST - 5 months ago

Kairos Pharma Provides Business Update and Outlook into 2025

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Jan 7, 2025, 8:15 AM EST - 6 months ago

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Kairos Pharma: Potential To Remove Resistance With Established Drugs

Dec 26, 2024, 7:51 AM EST - 6 months ago

Kairos Pharma: Potential To Remove Resistance With Established Drugs

Kairos Pharma to Participate in The Microcap Conference in January 2025

Dec 16, 2024, 12:15 PM EST - 6 months ago

Kairos Pharma to Participate in The Microcap Conference in January 2025

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Dec 3, 2024, 8:30 AM EST - 7 months ago

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

IBN Initiates Coverage of Kairos Pharma Ltd.

Nov 26, 2024, 8:30 AM EST - 7 months ago

IBN Initiates Coverage of Kairos Pharma Ltd.

Kairos Pharma to Present at the LD Micro Main Event XVII

Oct 22, 2024, 9:00 AM EDT - 8 months ago

Kairos Pharma to Present at the LD Micro Main Event XVII

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Oct 9, 2024, 4:30 PM EDT - 9 months ago

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

Sep 24, 2024, 4:20 PM EDT - 9 months ago

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

Sep 21, 2024, 2:00 AM EDT - 9 months ago

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

BIOA BKV FBGL GLE GRDN LGCY PRB

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Sep 17, 2024, 4:29 PM EDT - 10 months ago

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Kairos Pharma Prices $6.2 Million Initial Public Offering

Sep 16, 2024, 10:49 AM EDT - 10 months ago

Kairos Pharma Prices $6.2 Million Initial Public Offering

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Feb 14, 2024, 6:16 PM EST - 1 year ago

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Kairos Pharma Files For U.S. IPO

Oct 3, 2023, 3:33 PM EDT - 1 year ago

Kairos Pharma Files For U.S. IPO

SpartanVI
SpartanVI Jun. 25 at 7:54 AM
$KAPA looks ready for a move soon
0 · Reply
NL1211
NL1211 Jun. 24 at 8:40 PM
$KAPA guys, i am following this Kapa since many months. CEO said this month initial data. is it delayed or still in next 4 working days ?
0 · Reply
StrawberryRips
StrawberryRips Jun. 24 at 7:59 PM
$KAPA going green w a bullish hammer on the daily candle 👀
0 · Reply
StrawberryRips
StrawberryRips Jun. 24 at 6:58 PM
$KAPA weekly MACD curling… read it out
1 · Reply
SteadyTrade55
SteadyTrade55 Jun. 24 at 5:32 PM
$KAPA bull flag, on the 1 week chart. Basing beautifully
1 · Reply
lovestockstwits
lovestockstwits Jun. 24 at 4:45 PM
$KAPA worthless stock ..only stock red today
1 · Reply
Xtracked
Xtracked Jun. 24 at 2:04 PM
$KAPA Final dip! Last chance to load up. Healthy movement
0 · Reply
Winning_calls
Winning_calls Jun. 24 at 12:19 PM
$KAPA 😘😘🤞
0 · Reply
KingJames_
KingJames_ Jun. 24 at 12:08 AM
$KAPA ENV105 is meeting an unmet medical need with drug resistance. Big pharma is going to jump all over this!! This is going $9+
0 · Reply
StrawberryRips
StrawberryRips Jun. 23 at 8:35 PM
$KAPA FDA PHASE 2 Effectiveness Readout any minute now. Drug: ENV105 to combat cancer drug resistance. -aims to reverse the resistance that cancer cells develop against treatments. -only 1/100,000 patients beat cancer without treatment. Treatments are very necessary, so resistance to treatments can greatly affect the outcome of beating cancer. If the Phase 2 results are good this company is sitting on a breakthrough cancer treatment assistance drug. Small float, recently listed in 2024 so this isn’t your regular penny-stock reverse split rinse and repeat type of stock. High price targets on this one too: $4-12. Easy buy and hold.
2 · Reply
Bologna_Bill
Bologna_Bill Jun. 23 at 8:26 PM
$KAPA does anyone know when they are reporting the results of ENV‑105? Supposed to be before July correct? Thanks advance!
1 · Reply
Sillyguy
Sillyguy Jun. 23 at 7:08 PM
$KAPA Bears tapped
0 · Reply
StrawberryRips
StrawberryRips Jun. 23 at 6:48 PM
$KAPA ☕️
0 · Reply
StrawberryRips
StrawberryRips Jun. 23 at 6:28 PM
$KAPA hit .75 outside market hours twice. Something’s cooking here, and I’m not going to miss out. Anything under .70s is likely a gold mine short term.
0 · Reply
KingJames_
KingJames_ Jun. 23 at 6:21 PM
$KAPA
0 · Reply
StrawberryRips
StrawberryRips Jun. 23 at 5:40 PM
$SPY crazy moves. The rebound providing opportunities to add dips on the small caps that are lagging. $IXHL $KAPA
0 · Reply
StrawberryRips
StrawberryRips Jun. 23 at 5:00 PM
(pay)tience $IXHL $KAPA
0 · Reply
StrawberryRips
StrawberryRips Jun. 23 at 4:40 PM
Switched my smaller $LITM position to $KAPA for small loss. $KAPA performing well with news due this week 🤞👀 got caught chasing a bit tho…
0 · Reply
StrawberryRips
StrawberryRips Jun. 23 at 3:42 PM
$KAPA first half of the year about done-any minute there should be some PR. $IXHL company sounds super positive in PRs, easy hold with July approaching.
0 · Reply
Winning_calls
Winning_calls Jun. 23 at 2:42 PM
$KAPA 😘😘
0 · Reply
AstroFuel
AstroFuel Jun. 23 at 2:42 PM
$KAPA
0 · Reply
RollingDollars
RollingDollars Jun. 23 at 2:25 PM
$KAPA
0 · Reply